Company Overview and News
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819
KUALA LUMPUR (Oct 16): The FBM KLCI reversed its earlier losses and climbed at mid-morning, tracking the modest rise at the regional markets.
UPBMF 5220 7113 5681 TPGVF BATS 4162 2291 2089 5014 7066 0131 6033 7123 5199 TGLVY 4588 PNADF 0026 MYPRY HIPEF PNAGF GEBHF
KUALA LUMPUR (Oct 8): The FBM KLCI remained marginally in the negative zone, having pared much of its losses in the morning session today, against the backdrop of weaker regional markets.
SPMXF 7036 5681 5263 BATS 4162 1163 5256 7123 5199 SPMXY 5225 3026 3301 3867 1899 Q0F IHHHF HIPEF GEBHF
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF
KUALA LUMPUR, Oct 1 — Share prices on Bursa Malaysia were slightly higher at today's opening, despite the mixed performance seen in regional markets following the slowdown in China's manufacturing sector, a dealer said.
PBLOF 7036 1295 BSMAF HIPEF 7123 1818 5199
KUALA LUMPUR, Sept 24 — Bursa Malaysia snapped a three-session gains to end broadly lower pressured by selling in heavyweights stocks as most regional markets reacted negatively to renewed concerns over the US-China trade dispute, dealers said.
9385 PBLOF 1295 BSMAF HIPEF 7123 1818 5199
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF
KUALA LUMPUR, Sept 18 — Bursa Malaysia ended lower on continued selling of heavyweights in line with most regional markets as investors remained cautious amid renewed concerns over the US-China trade dispute, dealers said.
PBLOF 0026 1295 BSMAF 7123 1818
KUALA LUMPUR (Sept 18): The FBM KLCI fell 0.66% at midday break, as new tariffs announced by Washington on Chinese imports rattled regional markets.
HLFBF 7052 MLYNF 8621 9679 BATS 4162 2089 1783 1023 5225 IHHHF PNAGF HRGHY MLYBY UPBMF 1082 5681 5168 6033 7123 CIMDF 5238 1155 PNADF SGPBY 0026 Q0F
KUALA LUMPUR, Sept 18 — Bursa Malaysia ended the morning session lower, with the key composite index falling 0.65 per cent, despite mixed sentiment among regional peers due to renewed concerns over the US-China trade dispute, analysts said.
PBLOF 0026 1295 BSMAF 7123 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...